(Q46391449)

English

Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

author name string

A Spencer

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

N Horvath

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

J Gibson

3

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

H M Prince

4

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

R Herrmann

5

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

J Bashford

6

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

D Joske

7

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

A Grigg

8

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

J McKendrick

9

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

I Prosser

10

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

R Lowenthal

11

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

S Deveridge

12

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

K Taylor

13

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

Australasian Leukemia and Lymphoma Group

14

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

language of work or name

0 references

publication date

1 May 2005

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

35

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

10

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

971-977

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704946

0 references

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Radiation protectors: the unexpected benefits

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cellautotransplant: a retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Amifostine (WR-2721) selective protection against melphalan genotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group (NMSG)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose intravenous melphalan for plasma-cell leukaemia and myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple myeloma treated with high dose intravenous melphalan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

7 January 2021

based on heuristic

inferred from DOI database lookup

The modification of melphalan toxicity in tumor bearing mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR2721)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

7 January 2021

based on heuristic

inferred from DOI database lookup

Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive treatment of multiple myeloma and criteria for complete remission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

7 January 2021

based on heuristic

inferred from DOI database lookup

Amifostine (WR-2721) Protects Normal Haematopoietic Stem Cells Against Cyclophosphamide Derivatives' Toxicity Without Compromising Their Antileukaemic Effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1704946

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15778725

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46391449&oldid=2109209369"